Licensing Opportunities

Licensing and partnering opportunities are available for Amura’s drug discovery programmes, technologies and intellectual property portfolio.  Amura adopts a flexible approach to licensing and partnering opportunities and welcomes enquiries from interested parties.

Licensing and partnering opportunities are available for:

 AMcore™
AMcore™ provides a turnkey solution for the discovery of drugs directed towards commercially attractive therapeutic areas.  Amura is seeking partners with a common vision towards progression and commercialisation of these first in class therapeutics.

 AmLinker™
AmLinker™ provides a novel solution for 'linkage chemistry' addressing needs across the biologics, proteomics and genomics arenas.  Amura is seeking partners with a common vision towards progression and commercialisation of this exciting technology.

 ß-lactamase inhibitors
The ß-lactamase inhibitors (BLIs) are positioned as combination partner compounds for ß-lactam antibiotics including: penicillins, cephalosporins and carbapenems to be used in first-line i.v. treatments for broad-spectrum hospital-acquired bacterial infections.  Amura is seeking partners with a common vision towards progression and commercialisation of these combination therapeutics.

Contact details:

Dr. Dan Roach
Tel: +44(0)1954 211515
Email: DRoach@avlar.com